Akbar Soleimani1, Zahra Mobedi2, Maryam Al-E-Rasul3, Abolghasem Sharifi4, Abdolrahim Kazemi Vardanjani4. 1. Faculty, Department of Internal Medicine, Shahr-e-Kord University of Medical Sciences, Shahr-e-Kord, Iran. 2. Faculty, Department of Rheumatology, Shahr-e-Kord University of Medical Sciences, Shahr-e-Kord, Iran. 3. Faculty, Department of Gynaecology and Obstetrics, Shahr-e-Kord University of Medical Sciences, Shahr-e-Kord, Iran. 4. Deputy of Research and Technology, Shahr-e-Kord University of Medical Sciences, Shahr-e-Kord, Iran.
Abstract
INTRODUCTION: Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. AIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. MATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. RESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p<0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. CONCLUSION: RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.
INTRODUCTION:Rheumatoid arthritis (RA) is a crippling disease with a global prevalence of approximately 0.5%-1% in adults. Genetic, environmental and immunologic factors contribute importantly to pathogenesis of RA. American College of Rheumatology (ACR) assists in early diagnosis of the disease. AIM: The aim of this study was to investigate the effects of HLA-DRB1 gene and anti-Cyclic Citrullinated Peptide (CCP) antibody on Clinical Disease Activity Index (CDAI) and to determine the frequency of HLA-DRB1 alleles in the patients with RA. MATERIALS AND METHODS: In this descriptive-analytical study, 64 patients with RA referring rheumatology clinic of Hajar Hospital, Shahr-e-Kord, Iran were enrolled based on ACR criteria (1987) by convenience sampling. All patients were examined to assess primary CDAI and referred to laboratory for serologic tests [Rheumatoid Factor (RF) and anti-CCP]. After the patients' DNA was extracted, HLA-DRB1 was determined per single specific primer-polymerase chain reaction by inno-train kits. The patients were re-examined six months later. RESULTS: The most prevalent type of HLA-DRB1 in the studied patients was 04. In patients with HLA-DRB1 (04), HLA-DRB1 (01), and HLA-DRB1 (15), CDAI decreased pronouncedly after six months, but in other patients it did not (p<0.05). Of the patients, 81.3% had high titers of anti-CCP, but no association between anti-CCP and CDAI was found. CONCLUSION:RA could be a multifactorial disease. The patients with HLA-DRB1 (04), HLA-DRB1 (01) and HLA-DRB1 (15) showed a good response to routine treatments. The patients with HLA-DRB1 (04) are likely to have no decrease in secondary CDAI. High titers of anti-CCP in patients may indicate the severity of RA in the studied region and perhaps environmental, genetic and unknown or idiopathic factors are aetiologically crucial.
Entities:
Keywords:
Human leukocyte antigen; Rheumatic diseases; Rheumatoid Factor
Authors: S Mitsunaga; Y Suzuki; M Kuwana; S Sato; Y Kaneko; Y Homma; A Narita; K Kashiwase; Y Okudaira; I Inoue; J K Kulski; H Inoko Journal: Tissue Antigens Date: 2012-04-04
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Judit Laki; Emeli Lundström; Omri Snir; Johan Rönnelid; Izabella Ganji; Anca I Catrina; Camilla Bengtsson; Saedis Saevarsdottir; Marius C Wick; Lars Alfredsson; Lars Klareskog; Leonid Padyukov Journal: Arthritis Rheum Date: 2012-07
Authors: Ariana Montes; Rebeca Dieguez-Gonzalez; Eva Perez-Pampin; Manuel Calaza; Antonio Mera-Varela; Juan J Gomez-Reino; Antonio Gonzalez Journal: Arthritis Rheum Date: 2011-03
Authors: S L Mackie; J C Taylor; S G Martin; P Wordsworth; S Steer; A G Wilson; J Worthington; P Emery; J H Barrett; A W Morgan Journal: Genes Immun Date: 2011-09-01 Impact factor: 2.676
Authors: Joyce J B C van Beers; Annemiek Willemze; Judith Stammen-Vogelzangs; Jan W Drijfhout; René E M Toes; Ger J M Pruijn Journal: Arthritis Res Ther Date: 2012-02-17 Impact factor: 5.156